Superiority and clinical significance of Lunx mRNA in the diagnosis of malignant pleural effusion caused by pulmonary carcinoma

Journal of Experimental & Clinical Cancer Research

Lijun Xu¹  Ying Tang¹ 

[1]Department of Respiratory Medicine, the First Hospital of Jilin University, Changchun

[2] 130021, China

关键词: Lunx mRNA;    Pulmonary carcinoma;    Malignant pleural effusion;   

Others  :  824965
DOI  :  10.1186/1756-9966-32-37

 received in 2013-03-25, accepted in 2013-05-25,  发布年份 2013

【 摘 要 】

Background

Pulmonary carcinoma is the main cause of malignant pleural effusions (MPEs). However, there is no satisfactory marker for diagnosing MPEs caused by pulmonary carcinoma. The purpose of this study is to assess the clinical significance of Lunx mRNA detection in diagnosing MPEs caused by pulmonary carcinoma.

Methods

A total of 209 patients with pleural effusions were recruited. The patients were diagnosed by cast-off cells, bronchoscopy, and pleural biopsy. The levels of Lunx mRNA in the pleural effusions were determined by real-time PCR. The levels of PH, LDH, glucose, albumin, and CEA were also determined. Patients who accepted chemotherapy underwent Lunx mRNA detection before and after the first chemotherapy session. The patients were divided into four groups according the effect of chemotherapy: complete remission (CR), partial remission (PR), no change (NC), and progressive disease (PD). The patients were also divided into two groups according the change in direction of Lunx mRNA expression after chemotherapy: increased group and decreased group. The patients were followed up to determine survival.

Results

Lunx mRNA was positive in 89 of 106 patients with pleural effusions caused by pulmonary carcinoma. The specificity and sensitivity were 95.9% and 84.9%. The area under the ROC curve was 0.922. Lunx mRNA detection was better than detection using cast-off cells and CEA. All of the Lunx-positive patients with MPEs were diagnosed with pulmonary carcinoma, and all extrapulmonary carcinoma patients were Lunx-negative. The positive predictive value of Lunx mRNA for the source of tumor cells was 100%. Lunx mRNA expression decreased after the first session of chemotherapy in the CR and PR groups, increased in the PD group, there was no change in the NC group. Further analysis indicated the change in direction of Lunx mRNA expression was associated with the overall survival of patients. The patients in the increased group had longer overall survival times than those in the decreased group.

Conclusion

Lunx mRNA is a specific tumor gene that is highly expressed in MPEs caused by pulmonary carcinoma. The changes in Lunx mRNA levels after chemotherapy can predict the prognosis of patients with MPEs caused by pulmonary carcinoma.

【 授权许可】

   
2013 Tang and Xu; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Heffner JE, Klein JS: Recent Advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008, 83:235-250.
• [2]Medford A, Maskell N: Pleural effusion. Postgrad Med J 2005, 81:702-710.
• [3]Hermanek P, Hutter RVP, Sobin LH, Wittekind C: Classification of isolated tumor cells and micrometastasis. Cancer 1999, 86:2668-2673.
• [4]Raj GV, Moreno JG, Gomella LG: Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 1998, 82:1419-1442.
• [5]Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC: Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 1999, 17:1330.
• [6]NCCN Clinical Practice Guidelines in Oncology. Version 3. 2012. [http://www.NCCN.org webcite]
• [7]World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO Offset Publication; 1979. No. 48
• [8]Li X, Asmitananda T, Gao L, Gai D, Song Z, Zhang Y, Ren H, Yang T, Chen T, Chen M: Biomarkers in the lung cancer diagnosis: a clinical perspective. Neoplasma 2012, 59:500-507.
• [9]Schneider J: Tumor markers in detection of lung cancer. Adv Clin Chem 2006, 42:1-41.
• [10]Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH: Cytokeratin fragment 19 and squamous cell carcinoma antigen for early prediction of recurrence of squamous cell lung carcinoma. Am J Clin Oncol 2000, 23:241-243.
• [11]Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E: Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 2000, 20:5053-5058.
• [12]Iwao K, Watanabe T, Fujiwara Y, Takami K, Kodama K, Higashiyama M, Yokouchi H, Ozaki K, Monden M, Tanigami A: Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker for detection of micrometastasis in non-small-cell lung cancer. Int J Cancer 2001, 91:433-437.
• [13]Lv M, Wu MZ, Zhao YJ, Yang DI, Wang EH, Wu GP: Expression and clinical significance of lung-specific X protein mRNA in bronchial brushing specimens from patients with or without lung cancer. Respirology 2011, 16:1076-1080.
• [14]Mitas M, Hoover L, Silvestri G, Reed C, Green M, Turrisi AT, Sherman C, Mikhitarian K, Cole DJ, Block MI, Gillanders WE: Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn 2003, 5:237-242.
• [15]Wallace MB, Block MI, Gillanders W, Ravenel J, Hoffman BJ, Reed CE, Fraig M, Cole D, Mitas M: Accurate molecular detection of non-small cell lung cancer metastases in mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Chest 2005, 127:430-437.
• [16]Wang Y, Zhang Y, Du Z, Wu M, Zhang G: Detection of micrometastases in lung cancer with magnetic nanoparticles and quantum dots. Int J Nanomedicine. 2012, 7:2315-2324.
• [17]Cheng M, Chen Y, Yu X, Tian Z, Wei H: Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer 2008, 8:156. BioMed Central Full Text
• [18]Heffner JE: Management of the patient with a malignant pleural effusion. Semin Respir Crit Care Med 2010, 31:723-733.
• [19]Awasthi A, Gupta N, Srinivasan R, Nijhawan R, Rajwanshi A: Cytopathological spectrum of unusual malignant pleuraleffusions at a tertiary care centre in north India. Cytopathology 2007, 18:28-32.
• [20]Burrows CM, Mathews WC, Colt HG: Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000, 117:73-78.
• [21]Jeon CH, Shin KC, Choi EY, Jung SB: Detection of rare cancer cells in the blood by RNA extraction of filtered mononuclear cells and reverse transcription-PCR. J Lab Med Qual Assur 2011, 33:111-118.
• [22]Kastelik JA: Management of malignant pleural effusion. Lung 2013, 191:165-175.
• [23]Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H: Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005, 32:151-155.
• [24]Yu XQ, Cheng M, Zhang YB, Fang Y, Wang T: The role of LunX and CK19 expression in distinguishing malignant and nonmalignant plural fluids. Chin J Thorac Cardiovasc 2007, 23:327-328.